Go Pro

Chemomab Therapeutics (CMMB) News Today

Chemomab Therapeutics logo
$2.26 +0.09 (+4.15%)
As of 01:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Chemomab Therapeutics Latest News

Chemomab to merge with Scipher Medicine
Chemomab Therapeutics Ltd ADR CMMB
Chemomab Hikes on Q1 Figures
Chemomab reports promising PSC treatment data
Chemomab Announces New Medical and Clinical Appointments
Chemomab Therapeutics reports results in nebokitug Phase 2 PSC OLE trial

Chemomab Therapeutics Media Mentions By Week

Chemomab Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CMMB
News Sentiment

-1.00

0.67

Average
Healthcare
News Sentiment

Chemomab Therapeutics News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CMMB Articles
This Week

3

1

CMMB Articles
Average Week

Chemomab Therapeutics Trends on MarketBeat

This week vs. last week
Searches
2
+100%
Page Views
1,016
+13%
Get Chemomab Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Chemomab Therapeutics dated 8/19/2026.
From Our Partners